文献速递慢性肾脏病血液净化与透析

SGLT2抑制剂在2型糖尿病合并CKD患者中的安全性

Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD.
PubMed 文献 · Am J Kidney Dis · 2026-09-21

本研究利用美国两个大型医保数据库,纳入2型糖尿病合并CKD 3-4期患者,比较起始SGLT2抑制剂与GLP-1受体激动剂后的不良事件。经倾向性评分匹配和树状扫描统计发现,SGLT2抑制剂在门诊诊断中显示生殖器感染安全信号(P<0.001),但住院/急诊诊断未发现安全信号,未识别新的安全性问题。

要点

  • SGLT2抑制剂在T2DM合并CKD患者中与生殖器感染风险增加相关。
  • 基于住院和急诊诊断未发现SGLT2抑制剂的其他安全信号。
  • 未观察到与SGLT2抑制剂相关的新的或未知不良事件。

核心结论

  • 在2型糖尿病合并CKD患者中,与GLP-1受体激动剂相比,SGLT2抑制剂未发现新的安全信号,仅识别出已知的生殖器感染风险。

主要发现

  • 在Medicare和MarketScan两个队列中,基于门诊诊断代码,SGLT2抑制剂起始在女性和男性中均显示生殖器感染安全信号(P < 0.001)。
  • 基于住院/急诊诊断代码,树状扫描统计未检测到任何安全信号。

临床怎么用

  • 在T2DM合并CKD患者中使用SGLT2抑制剂时,应关注生殖器感染风险,但无需担忧其他未预期的严重不良事件。

局限性

  • 存在残余混杂、潜在的错误分类和统计功效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) are often underrepresented in clinical trials evaluating the safety profile of newer medication classes for type 2 diabetes (T2DM). Given the high burden of comorbidities and polypharmacy in this population, further safety research is needed. This study detected potential adverse events associated with sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with T2DM and CKD using a tree-based scan statistic approach. STUDY DESIGN: New-user active comparator cohort study. SETTING & PARTICIPANTS: Medicare Fee-for-Service data (October 2016 to December 2020) and the Merative MarketScan commercial claims database (October 2016 to December 2022) used to identify patients aged ≥65 years (Medicare) or ≥18 years (MarketScan) with T2DM and CKD (stages 3-4). EXPOSURE: New use of SGLT2 inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists. OUTCOME: ICD-10 coded adverse outcome events in outpatient, inpatient, or emergency department settings. ANALYTIC APPROACH: After 1:1 propensity-score matching, a hierarchical data-mining surveillance method using ICD-10 outcomes, a tree-based scan statistic, to identify signals for incident adverse events. RESULTS: We identified 22,328 matched pairs in Medicare (mean age, 74 years; 45% women) and 8,918 matched pairs in MarketScan (mean age, 65 years; 42% women). In both cohorts, based on outpatient diagnosis codes, SGLT2 inhibitor initiation showed safety signals for genital infections in both women and men (P < 0.001). However, the tree-based scan statistic did not detect any safety signals based on inpatient/emergency department diagnosis codes. LIMITATIONS: Residual confounding, potential misclassification, and limited power. CONCLUSIONS: In 2 large real-world cohorts of patients with T2DM and CKD, the tree-based scan statistic identified previously known adverse events but no new safety signals associated with SGLT2 inhibitor use compared with GLP-1 receptor agonist use. PLAIN-LANGUAGE SUMMARY: Patients with type 2 diabetes and chronic kidney disease are frequently underrepresented in clinical trials of newer diabetes drugs. This study sought to better understand the safety of sodium/glucose cotransporter 2 (SGLT2) inhibitors, a newer diabetes medication class, in this high-risk population. Using 2 large US health insurance databases, we compared adults who started an SGLT2 inhibitor with similar patients who started a different class of commonly used medications for diabetes, glucagon-like peptide 1 receptor agonists. The study used a data-driven method to scan for possible side effects. It identified that genital infections are more common with use of SGLT2 inhibitors, an association that has been previously recognized, but no additional new safety concerns. Identifying the same safety signal pattern that was seen in prior studies of SGLT2 inhibitors using a different data-driven scanning approach provides reassurance that we understand the safety and risk profile of this class of drugs.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ortega-Montiel J, Alkabbani W, Hahn G, et al. Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD. Am J Kidney Dis. 2026. PMID: 42767321. doi:10.1053/j.ajkd.2026.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。